(Q40510093)

21 September 2017

title

Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240. (English)

1 reference

21 September 2017

Marc Pfister

1

1 reference

21 September 2017

Nancy E Martin

series ordinal

2

1 reference

21 September 2017

Lloyd P Haskell

series ordinal

3

1 reference

21 September 2017

Jeffrey S Barrett

series ordinal

4

1 reference

21 September 2017

language of work or name

1 reference

1 June 2004

1 reference

The Journal of Clinical Pharmacology

21 September 2017

published in

1 reference

21 September 2017

volume

44

1 reference

21 September 2017

issue

6

1 reference

21 September 2017

page(s)

621-631

1 reference

21 September 2017

cites work

Vasopeptidase inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Neutral endopeptidase inhibition: the potential of a new therapeutic approach in cardiovascular disease evolves

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Hypotensive and natriuretic actions of adrenomedullin in subjects with chronic renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Neprilysin inhibitors potentiate effects of bradykinin on b2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Plasma bradykinin in angio-oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Pharmacokinetic-pharmacodynamic modelling of magnesium plasma concentration and blood pressure in preeclamptic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Effects of a 1 day fast on biohumoral variables associated with human circadian rhythmicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004265365

21 January 2018

Identifiers

DOI

10.1177/0091270004265365

1 reference

21 September 2017

1 reference